Boron-containing small molecules

1. A compound, or a salt or a hydrate or a solvate thereof, having a structure which is:

wherein

W is H or a bond to X;

X is

 wherein

R a and R b are each independently selected from the group consisting of R 15 , —OR 15 , —NR 15 R 16 , —SR 15 , —S(O)R 15 , —S(O) 2 R 15 , —S(O) 2 NR 15 R 16 , —C(O)R 15 , —C(O)OR 15 , and —C(O)NR 15 R 16 ,

wherein R 15 and R 16 are each independently selected from the group consisting of H, halogen, cyano, nitro, —OR 17 , —NR 17 R 18 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl,

wherein R 17 and R 18 are each independently selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl,

and wherein R 15 and R 16 , and/or R 17 and R 18 , along with the nitrogen to which they are connected, are optionally joined to form a substituted or unsubstituted 4- to 8-membered ring,

with the proviso that R a and R b are not both H;

or X is

 wherein

R c is —OR 15 , —NR 15 R 16 , —SR 15 , —S(O)R 15 , —S(O) 2 R 15 , —S(O) 2 NR 15 R 16 , —C(O)R 15 , —C(O)OR 15 , and —C(O)NR 15 R 16 ,

wherein R 15 and R 16 are each independently selected from the group consisting of H, halogen, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl,

and wherein R 15 and R 16 , along with the nitrogen to which they are connected, are optionally joined to form a substituted or unsubstituted 4- to 8-membered ring;

or X is

 wherein

R d and R e are each independently selected from the group consisting of H, halogen, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl, —OR 15 , —NR 15 R 16 , —S(O)R 15 , —S(O) 2 R 15 , —S(O) 2 NR 15 R 16 , —C(O)R 15 , —C(O)OR 15 , and —C(O)NR 15 R 16 —,

wherein R 15 and R 16 are each independently selected from the group consisting of H, halogen, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl,

and wherein R d and R e , along with the atom to which they are connected, are optionally joined to form a substituted or unsubstituted 3- to 8-membered ring,

and wherein R 15 and R 16 , along with the nitrogen to which they are connected, are optionally joined to form a substituted or unsubstituted 4- to 8-membered ring,

with the proviso that R d and R e are not both H,

wherein X optionally comprises an attachment point to W;

Y is selected from the group consisting of a bond, —O—, —S—, —NH—, substituted or unsubstituted alkylene, and substituted or unsubstituted heteroalkylene;

Z is a substituted or unsubstituted heterocyclic ring or ring system containing at least one endocyclic boron; and

the substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted alkylene, substituted heteroalkylene, s substituted aryl, and substituted heteroaryl are respectively alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl respectively substituted with one or more substituents selected from the group consisting of —R′, —OR′, ═O, NR′, ═N—OR′, —NR′R″, —SR′, halogen, —SiR′R″R′″, —OC(O)R′, —C(O)R′, —CO 2 R′, —CONR′R″, —OC(O)NR′R″, —NR″C(O)R′, —NR′—C(O)NR″R′″, —NR″C(O) 2 R′, —NR′″″—C(NR′R″R′″)═NR″″, —NR″″—C(NR′R″)═NR′″, —S(O)R′, —S(O) 2 R′, —S(O) 2 NR′R″, —NR″SO 2 R′, —CN, —NO 2 , —CH(Ph) 2 , fluoro(C 1 -C 4 )alkoxy, and fluoro(C 1 -C 4 )alkyl,

wherein R′, R″, R′″, R″″ and R′″″ are each independently selected from the group consisting of hydrogen, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, aryl substituted with 1-3 halogens, substituted or unsubstituted alkyl, alkoxy or thioalkoxy groups, and arylalkyl groups.

2. The compound of claim 1 , or a salt or a hydrate or a solvate thereof, wherein said X is

wherein

R 15 is selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.

3. The compound of claim 1 , or a salt or a hydrate or a solvate thereof, wherein said X is

wherein

R 15 and R 16 are each independently selected from the group consisting of H, —NR 17 R 18 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl

wherein R 17 and R 18 are each independently selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl

and wherein R 15 and R 16 , and/or R 17 and R 18 , along with the nitrogen to which they are connected, are optionally joined to form a substituted or unsubstituted 4- to 8-membered ring.

4. The compound of claim 1 , or a salt or a hydrate or a solvate thereof, wherein said X is

wherein

R c is selected from the group consisting of H, substituted or unsubstituted alkyl, and —OR 15

wherein R 15 is H or substituted or unsubstituted alkyl.

5. The compound of claim 1 , or a salt or a hydrate or a solvate thereof, wherein said X is

wherein

R d is selected from the group consisting of halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, —OR 15 , —SR 15 , —S(O)R 15 , —NR 15 R 16 , —C(O)R 15 , —CH 2 C(O)OR 15 , and —CH 2 C(O)NR 15 R 16

wherein R 15 and R 16 are each independently selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl

and wherein R 15 and R 16 , along with the nitrogen to which they are connected, are optionally joined to form a substituted or unsubstituted 4- to 8-membered ring.

6. The compound of claim 5 , or a salt or a hydrate or a solvate thereof, wherein R d comprises said attachment point to W.

7. The compound of claim 1 , or a salt or a hydrate or a solvate thereof, wherein said Y is *—OCH 2 — or *—SCH 2 — or *—NHCH 2 — or *—CH 2 NH— or *—C(O)NH—, wherein * represents the attachment point to said Z.

8. The compound of claim 1 , or a salt or a hydrate or a solvate thereof, wherein said Z is selected from the group consisting of substituted or unsubstituted benzoxaborole, substituted or unsubstituted pyridinyloxaborole, substituted or unsubstituted benzoxaborininol, substituted or unsubstituted benzoxazaborininol, substituted or unsubstituted benzodiazaborininol, and substituted or unsubstituted oxaborole.

9. The compound of claim 8 , or a salt or a hydrate or a solvate thereof, wherein said Z is

wherein

R 3 , R 3a , R 4 , R 5 , and R 7 are each independently selected from the group consisting of R 10 , —OR 10 , —NR 10 R 11 , —SR 10 , —S(O)R 10 , —S(O) 2 R 10 , —S(O) 2 NR 10 R 11 , —C(O)R 10 , —C(O)OR 10 , and —C(O)NR 10 R 11

wherein

R 10 and R 11 are each independently selected from the group consisting of H, halogen, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.

10. The compound of claim 9 , or a salt or a hydrate or a solvate thereof, wherein said Z is

wherein

R 4 , R 5 , and Ware each independently selected from the group consisting of R 10 , —OR 10 , —NR 10 R 11 ,

wherein

R 10 and R 11 are each independently selected from the group consisting of H, halogen, cyano, nitro, substituted or unsubstituted alkyl, and substituted or unsubstituted heteroalkyl.

11. The compound of claim 10 , or a salt or a hydrate or a solvate thereof, wherein said Z is

12. A combination comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, together with at least one other therapeutically active agent.

13. The combination of claim 12 , or a pharmaceutically acceptable salt or a hydrate or a solvate thereof, wherein the other therapeutically active agent is an anti-bacterial agent.

14. A pharmaceutical formulation comprising:

a) the compound of claim 1 , or a pharmaceutically acceptable salt or a hydrate or a solvate thereof; and

b) a pharmaceutically acceptable excipient.

15. A method of inhibiting protein synthesis in a bacteria, the method comprising contacting the bacteria with the compound of claim 1 , or a pharmaceutically acceptable salt or a hydrate or a solvate thereof, thereby inhibiting protein synthesis in the bacteria.

16. A method of inhibiting the growth of and/or killing a bacteria, the method comprising contacting the bacteria with the compound of claim 1 , or a pharmaceutically acceptable salt or a hydrate or a solvate thereof, thereby inhibiting the growth of and/or killing the bacteria.

17. The method of claim 15 , wherein the bacteria is Gram-positive.

18. The method of claim 17 , wherein the bacteria is selected from the group consisting of Staphylococcus aureus, Streptococcus pneumoniae , methicillin-resistant Staphylococcus aureus, Wolbachia pipientis , and bacteria of the Wolbachia genus.

19. A method of treating a disease associated with a Gram-positive bacteria, and/or a worm in an animal, the method comprising administering to the animal a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt or a hydrate or a solvate thereof, thereby treating the disease.

20. The method of claim 19 , wherein the disease is associated with a Gram-positive bacteria.

21. The method of claim 19 , wherein the disease is selected from the group consisting of pneumonia, hospital-acquired pneumonia, hospital-associated pneumonia, community-acquired pneumonia, acute bacterial skin and skin-structure infection (ABSSSI), bacteremia, endocarditis, osteomyelitis, gastroenteritis, toxic shock syndrome, meningitis, septic arthritis, urinary tract infection, skin and skin-structure infection, strep throat, necrotizing fasciitis, otitis media, sinusitis, actinomycosis, diptheria, anthrax, food poisoning, botulism, tetanus, gas gangrene, diarrhea, tuberculosis, leprosy, candidiasis, aspergillosis, coccidioidomycosis, cryptococcosis, histoplasmosis, blastomycosis, paracoccidioidomycosis, zygomycosis, phaeohyphomycosis, rhinosporidiosis, enterobiasis, filariasis, lymphatic filariasis, bancroftian filariasis, subcutaneous filariasis, serious cavity filariasis, elephantiasis, elephantiasis tropica, lymphadenitis, lymphangitis, lymphedema, and onchocerciasis.